CUREVAC NV (CVAC)

CureVac stock plunges after German court rules against it in BioNTech patent challenge

CureVacs stock plunges as German court invalidates patent, boosting rival BioNTechs shares.

Pfizer stock hits 52-week low on weak guidance (NYSE:PFE)

Pfizer (PFE) shares hit a new low and its peers including Moderna (MRNA) and Novavax (NVAX) slipped as its 2024 outlook disappointed investors. Read more here.

CureVac BV reports Q3 results (NASDAQ:CVAC)

CureVac BV reports Q3 pre-tax loss of €47.7M and a revenue drop of 32.1% Y/Y, reflecting a challenging financial period for the company.

CureVac is Now Oversold (CVAC)

Why CureVac Stock Plunged Today

A German court temporarily suspended proceedings in CureVac's IP lawsuit against BioNTech.

CureVac is Now Oversold (CVAC)

CureVac Breaks Below 200-Day Moving Average - Notable for CVAC

Notable Two Hundred Day Moving Average Cross - CVAC

CureVac stock falls as science chief resigns (NASDAQ:CVAC)

CureVac (CVAC) trended lower pre-market Friday after announcing that its Chief Scientific Officer, Igor Splawski, would resign on July 14. Read more here.

CureVac-Pfizer/BioNTech patent fight extends to updated COVID shots

The patent dispute between CureVac (CVAC) and Pfizer (PFE) and BioNTech (BNTX) in Germany has been expanded to updated COVID shots. Read the full story here.

Why Shares of CureVac Jumped This Week

The company, which focuses on mRNA therapies, began a phase 1 trial for its cancer vaccine candidate.

Why CureVac Stock Leaped 12% Higher Today

The war on cancer advances with the German company's latest clinical development.

Vaccine stocks rise amid fears of new COVID wave in China (NASDAQ:CVAC)

Despite sharp year-to-date declines, shares of leading COVID-19 vaccine makers spiked Tuesday amid fears that China is facing a new wave of infections. Read more here.

CureVac accelerates COVID patent row with Pfizer/BioNTech (NASDAQ:CVAC)

CureVac (CVAC) announced Friday that its motion to transfer the ongoing patent litigation filed by Pfizer (PFE)/BioNTech (BNTX) has been granted. Rad more here.

CVAC Makes Bullish Cross Above Critical Moving Average

Relative Strength Alert For CureVac

Moderna Hypes 'Important Step' In Flu Shot Results, But Market Disagrees

Shares crumbled after Moderna's flu shot outperformed in just one flu strain.

Why did CureVac stock slip today? Declining market for COVID vaccines (NASDAQ:CVAC)

CureVac (CVAC) shares dropped ~7% Tuesday likely due to comments Pfizer made earlier in the day that it expects a 64% drop in revenue from its COVID-19 vaccine.

CureVac rises ~6% on positive data from COVID-19 and flue vaccine candidate (NASDAQ:CVAC)

CureVac (CVAC) is trading 5.6% higher premarket after it announced positive data from its Phase 1 trial of its vaccine candidate, CV0501, to treat COVID-19 in collaboration with...

The 3 Best Biotech Stocks Under $1 to Buy for January

Even the best small biotech stocks can go bust on a single bad study, but the winners can make their early investors rich.